Adamis Pharmaceuticals Corp reports results for the quarter ended in June - Earnings Summary

DMK Pharmaceuticals

10/08/2022 22:03

* Adamis Pharmaceuticals Corp  ADMP.OQ  reported a quarterly
adjusted loss of 6 cents​​ per share for the quarter ended in
June. The mean expectation of two analysts for the quarter was
for a loss of 4 cents per share.
    * Revenue fell 99% to $39.85 thousand from a year ago;
analysts
expected $1.02 million. 
    * Adamis Pharmaceuticals Corp's reported EPS for the quarter
was a
loss of 6 cents​.
    * The mean earnings estimate of analysts had fallen by
about 16.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Adamis Pharmaceuticals Corp shares had fallen by 26.1%
this
quarter and lost 38.8% so far this year.
    * The company reported a quarterly loss of $8.4 million.
    * Wall Street's median 12-month price target for Adamis
Pharmaceuticals Corp is $0.42 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.03          -0.06          Missed
 Mar. 31 2022      -0.03          -0.07          Missed
 Dec. 31 2021      -0.04          -0.06          Missed
 Sep. 30 2021      -0.04          -0.11          Missed